PUBLISHER: Grand View Research | PRODUCT CODE: 1941508
PUBLISHER: Grand View Research | PRODUCT CODE: 1941508
The global prefilled syringes market size was estimated at USD 8.72 billion in 2025 and is projected to reach USD 18.12 billion by 2033, growing at a CAGR of 9.7% from 2026 to 2033. The growing elderly population has led to an increase in the demand for prefilled syringes for the primary diagnosis and treatment of numerous chronic health ailments.
It has been recognized that people above 65 years of age are at a higher risk of developing severe health problems, such as heart disease, common asthma, cold & flu, COPD, diabetes, and other medical conditions. This is because aging weakens the immune system and increases an individual's susceptibility to various disorders.
The rising geriatric population and its associated burden of chronic conditions are propelling hospital admission rates. According to the CDC, adults aged 65 years & above are more likely to suffer from heart disease, COPD, diabetes, cancer, neurological problems, and other chronic illnesses. Patients with such illnesses require emergency & nonemergency hospital services and surgeries. The rising prevalence of chronic diseases globally is a key factor expected to drive market growth. Factors such as antimicrobial resistance, unhealthy & sedentary lifestyles, and tobacco & alcohol consumption are contributing to the rising prevalence of Non-communicable Diseases (NCDs). For instance, as per WHO data published in September 2023, around 41 million people succumb to NCDs annually, corresponding to 74% of all deaths worldwide. These factors are expected to drive the demand for prefilled syringes in the market. Prefilled sterile water syringes are increasingly used in healthcare settings for drug reconstitution, catheter flushing, and wound irrigation, as they eliminate manual preparation and reduce contamination risks, thereby supporting efficient clinical workflows and improving patient safety.
Needle-stick Injuries (NSIs) are percutaneous piercing wounds caused by needle tips. These injuries can occur while using, handling, disassembling, or disposing of syringes. The high incidence rate of NSIs and associated consequences is prompting healthcare professionals to use syringes with a safety mechanism. This is expected to boost the market over the forecast period. An intravenous cannula (33.0%) followed by a hypodermic needle (18.7%) were the most common devices involved in most NSIs. More than half of NSIs occurred during the use of sharp devices (52.7%), while 22.0% occurred after use and before disposal. About 42.9% of injuries happened in the patient room.
Furthermore, unsafe injections can lead to abscesses, septicemia, nerve damage, and hemorrhagic fevers. The rise in concerns regarding NSIs among both patients and healthcare professionals is one of the major factors expected to drive market growth. For instance, Sharps Technology, Inc. patented the best-in-class, single-use smart safety syringe products. In the same year, the company announced the acquisition of Safeguard Medical's syringe manufacturing facility in Hungary. These recent developments by pharmaceutical companies are expected to ensure safe injection practices, minimizing the chances of contamination. Double-chamber prefilled syringes further support safe injection practices by allowing the drug and diluent to be stored separately and mixed just before administration, reducing handling steps and contamination risk. This design is especially beneficial for lyophilized drugs and biologics, improving drug stability, dosing accuracy, and overall patient safety.
In addition to these factors, the growing number of approvals for prefilled syringes by regulatory bodies, such as the U.S. FDA, along with market expansion, is predicted to contribute to industry expansion actively. For instance, in September 2022, Owen Mumford Pharmaceutical Services, a company of Owen Mumford Ltd., received approval as a combination product in Asia for their safety device, 1mL UniSafe, for prefilled syringes. Moreover, the 1mL UniSafe has received regulatory approval in Europe, and the medicine is currently available on the market as a combination product with a rheumatoid arthritis drug. This safety device is a revolutionary, spring-free, patented safety mechanism for prefilled syringes that delivers a variety of benefits to pharmaceutical firms and their patients. Such developments are anticipated to increase the demand for prefilled syringes over the forecast period.
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global prefilled syringes market report based on type, material, application, distribution channel, and region: